JNJ-81201887 (AAVCAGsCD59)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for JNJ-81201887 (AAVCAGsCD59), covering 2026-03-13 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) [Phase 2]